Physician profile
Nathan A Hill
NPI 1679559405
$4,383.18
in general payments reported to CMS, 2019-2025
22 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $861 · 2021: $1,107 · 2022: $492 · 2023: $326 · 2024: $430 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,391.29 | 2019-2025 | Belbuca, Xtampza |
| Biodelivery Sciences International, INC. | $552.49 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $548.01 | 2019-2022 | |
| Pfizer INC. | $487.31 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $218.44 | 2023-2025 | Horizant, Edarbi |
| Arbor Pharmaceuticals, INC. | $211.07 | 2020-2021 | |
| Almatica Pharma LLC | $203.01 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $127.30 | 2023-2024 | Quviviq |
| Valinor Pharma, LLC | $105.20 | 2025 | Movantik |
| Redhill Biopharma INC. | $84.17 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.06 | 2019 | |
| Assertio Therapeutics, INC. | $55.32 | 2019 | |
| West Therapeutics Development, LLC | $46.41 | 2020-2021 | |
| Nevro Corp. | $44.03 | 2024 | Senza |
| Vertex Pharmaceuticals Incorporated | $43.87 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.07 | 2021 | |
| Daiichi Sankyo INC. | $38.55 | 2019 | |
| Horizon Therapeutics Plc | $33.65 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.59 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $21.68 | 2022 | |
| Protega Pharmaceutials INC | $18.78 | 2023 | Roxybond |
| Organogenesis INC. | $15.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.